News
Homepage
/
News
/
In 2023

News Classification

Check category

News Center

Viwit Pharmaceutical’s Lifitegrast API has completed registrations in both China and the US! 2024-08-14 11:55:51
Recently, Viwit Pharmaceutical’s self-developed Lifitegrast API has completed the registrations in China and the United States. The API registration number is Y20240000726, and the US DMF number is 040172.
Viwit Pharmaceutical's Varenicline Tartrate Tablet receives official approval from South Africa 2024-07-15 10:01:41
Recently, theViwit independently developed smoking cessation drug Varenicline (Tartrate) Tablets, in strengths of 0.5 mg and 1 mg, received the Drug Registration Certificate issued by the South African Health Products Regulatory Authority (SAHPRA).
Viwit Pharmaceutical's Fosaprepitant Dimeglumine API Receives Official Approval from NMPA 2024-07-12 09:12:19
On July 5, 2024, Viwit Pharmaceitical’s independently developed Fosaprepitant Dimeglumine API received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA). The registration number is Y20220000736, and the notice number is 2024YS00664.
Viwit Pharmaceuticals' Bimatoprost Eye Drops Receive Official Approval by China NMPA 2024-07-09 10:54:01
Recently, Viwit Pharmaceuticals received the "Drug registration certificate" issued by China National Medical Products Administration (NMPA) for Bimatoprost Eye Drops. The approval number is H20244103. This signifies that the product has received official approval for the Chinese market and has successfully passed the generic drug consistency evaluation, thereby becoming the second domestic generic drug of its kind.
Viwit Pharmaceuticals' Gadoterate Meglumine Injection Receives Official Approval by China NMPA 2024-06-17 15:13:15
Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for their Gadoterate Meglumine Injection. This approval includes the following strengths: 10 mL containing 3.769 g, 15 mL containing 5.654 g, and 20 mL containing 7.538 g. The corresponding approval numbers are H20243899, H20243900, and H20243901.
Viwit Pharmaceuticals' Deslanoside Injection Receives Official Approval by China NMPA 2024-06-15 10:26:00
May 8, 2024 – Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for the drug product, Deslanoside Injection. The approval notice number is 2024B01980.

In 2023

12-22

Viwit Pharmaceuticals' Vildagliptin Tablets Receive Official Approval by China NMPA

Viwit Pharmaceuticals is pleased to announce the acquisition of the Drug Registration Certificate (Certificate No: 2023S01974) from the National Medical Products Administration (NMPA) for a proprietary finished dosage form, Vildagliptin tablet. This signifies the official approval of this product in the Chinese market.
Viwit Pharmaceuticals' Vildagliptin Tablets Receive Official Approval by China NMPA
12-19

Viwit Pharmaceuticals' Lidocaine Injection Receives Official Approval by China NMPA

On December 18, 2023, Viwit Pharmaceuticals received the "Drug Supplementary Application Approval Notice" (Notice No: 2023B06224) issued by the China National Medical Products Administration for a proprietary finished dosage form, Lidocaine Hydrochloride for Injection (5ml: 0.1g).
Viwit Pharmaceuticals' Lidocaine Injection Receives Official Approval by China NMPA
12-07

Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA

On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.
Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA
10-31

Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA

On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.
Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA
10-30

Viwit Pharmaceuticals obtained the Drug Production License C

Congratulations to Viwit Pharmaceuticals that Viwit obtained the Drug Production License C for solid preparations and injections on July 28th, 2023. Meaning, that Viwit’s production lines for solid preparations and injections own the qualification on contracted manufacturing.
Viwit Pharmaceuticals obtained the Drug Production License C
10-18

Viwit Pharmaceuticals’BFS Technology

Viwit’s sterile blow-fill-seal (BFS) eye drops manufacturing facility is established in 2021. The BFS production line fulfills the need for an advanced aseptic manufacturing process using the state of the art Rommelag 434 BFS system. Pharmaceutical grade low-density polyethylene (PE) is used to ensure product quality and prevent leachable and leakage. A strip of 15 doses attached to each other can be created and filled within a few seconds. Every single BFS ampule is detected for leakage to ensure the integrity of the dose.
Viwit Pharmaceuticals’BFS Technology
09-18

Meeting Viwit Pharmaceuticals at CPHI Barcelona

Viwit Pharmaceuticals will be participating in CPHI Barcelona 2023 in Oct. 24th~26th, 2023 at Fira Barcelona Gran Via, Spain. Welcome to visit our booth 7D30 or contact us to learn more about our full portfolio of products, services, and solutions. We look forward to seeing you soon!
Meeting Viwit Pharmaceuticals at CPHI Barcelona
Previous page
1
2
search
Confirm
Close
About Us
Company Introduction Corporate History Business Introduction Corporate Governance Company Culture Corporate Honors Viwit Family Media Center Video
R&D and Innovation
R&D Innovation Product Pipeline Achievements
Products
Drug Products Biologics APIs Intermediates Boranes OLED Materials
Innovation
CDMO Project Collaboration In-/Out-Licensing Joint Venture
Sustainable
EHS Energy Quality Supplier
News Center
In 2024 In 2023 In 2022 In 2021 In 2020
Join Us
Talent Philosophy Talent Development Salary and Benefits Campus Recruiting Social Recruitment
Contact Us
Online Message Contact Us
dp EN
dp 中文

wz

wz